Researchers from the Umea pharmaceutical research company Quretech Bio have been granted SEK 5 million by the Erling-Persson Family Foundation to make resistant bacteria sensitive to antibiotics again.
“We are delighted and extremely grateful. This money is vital in allowing us to continue conducting critical experiments” says Jörgen Johansson, Professor of Molecular Microbiology at Umeå University and Co-founder of Quretech Bio.
Antibiotic-resistant bacteria are a growing problem and can lead to certain medicines becoming ineffective. Quretech Bio, which operates from the Umeå Biotech Incubator, wants to combat this problem by developing new medicines that either disarm bacteria instead of killing them or amplifies the effect of existing antibiotics.
Now, thanks to an application by Jörgen Johansson, researchers at Quretech Bio have been awarded SEK 5 million from the Erling-Persson Family Foundation.
For more information contact:
Fredrik Almqvist, PhD
Quretech Bio Co-Founder and CEO
fredrik.almqvist@quretech.com
+46 70-397 90 97
Jörgen Johansson, PhD
Quretech Bio Co-Founder and Board Member
jorgen.johansson@quretech.com
+46 76-107 39 47